[Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
146 patients with multiple sclerosis are treated by copaxone in the Moscow MS Centre. The relaps exacerbation rate decreased by 72%, the relapse rate reduced by 25.6% during the copaxone treatment. EDSS score did not increase both in group with and without relapses. The condition of 2/3 patients was stable. To achieve the best effect of treatment the program of patient support was successfully used in the Moscow MS Centre.
Demina
T L
TL
Davydovskaia
M V
MV
Lashch
N Iu
NIu
Popova
N F
NF
Khachanova
N V
NV
Zhuchenko
T D
TD
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001369:Axons / Q000473:pathology; D001921:Brain / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D000068717:Glatiramer Acetate; D006684:HLA-DR Antigens / Q000187:drug effects / Q000276:immunology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D006684:HLA-DR Antigens; D010455:Peptides; D000068717:Glatiramer Acetate